Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

Video • Mini-bones from the lab

Toward a personalized approach of bone cancer research and therapy

Researchers generated human mini bones in the lab which mirror the composition and function of human bone - a step toward the development of future patient-tailored models of bone cancers and tumors.

News • Driving genes of AMR in focus

Tracking the global spread of antimicrobial resistance

An international research team has provided valuable new information about what drives the global spread of genes responsible for antimicrobial resistance (AMR) in bacteria.

News • High-sensitivity blood test

New cancer testing method to make regular monitoring affordable

Scientists from Singapore discovered a novel low-cost method of testing for cancers. The test sequences heated clinical samples to isolate cancer-specific signatures found in a patient’s blood.